Reuters AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial